Why Is OMEROS CORP (OMER) Stock Down Today?

Omeros Corp shares fell 14.13% to $16.14 on Friday, driven by a renewed regulatory setback in Europe. The European Medicines Agency’s Committee for Medicinal Products for Human Use reaffirmed a negative opinion on narsoplimab, a therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy. This decision follows a prior negative opinion adopted in June 2026 and marks the second rejection of the application in the region.

What Happened

The stock opened at $18.12, a 3.6% gap down from the previous close of $18.79. The session low reached $15.89 at 10:05 AM ET before the price stabilized near $16.06. Omeros stated that the CHMP issued the negative opinion after a re-examination of the marketing authorization application. The company noted that the European outcome contrasts with the United States, where the therapy has received approval.

Cantor Fitzgerald reiterated an Overweight rating on the stock and maintained a $22 price target following the news. The company also announced that its compassionate-use program has ended. The move brings the stock below key technical support levels for the first time in nearly three months.

What The Data Shows

Volume for the session stood at 1.5 million shares, which is 0.8 times the three-month daily average. The stock printed 12 fresh 52-week lows on October 16, 2026. Fundamentals show a market capitalization of $1.3 billion, a P/E ratio of 12.8, and a net margin of 324.9%. The 52-week range is $6.24 to $21.24.

Recent insider activity indicates selling pressure, with six sales totaling $2.2 million in the last 90 days and no buys. David J. Borges, VP of Finance and CAO, sold shares on September 22, 2026. Peter B. Cancelmo, VP and General Counsel, sold on August 28, 2026, and Arnold C. Hanish, a director, sold on August 26, 2026. The stock had a beta of 2.57 and moved up 1.5% over the previous eight sessions.

What To Watch

Investors will monitor the company’s response to the European decision and any updates regarding its U.S. commercial strategy. The coverage breadth includes eight stories from seven sources in the last 36 hours, with analysts continuing to evaluate the long-term potential of the narsoplimab franchise despite the regional regulatory hurdles.